WINT vs. BGXX, BCDA, INAB, HOTH, CSCI, DWTX, BLRX, ATHA, PHXM, and LSB
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Bright Green (BGXX), BioCardia (BCDA), IN8bio (INAB), Hoth Therapeutics (HOTH), COSCIENS Biopharma (CSCI), Dogwood Therapeutics (DWTX), BioLineRx (BLRX), Athira Pharma (ATHA), PHAXIAM Therapeutics (PHXM), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs.
Windtree Therapeutics (NASDAQ:WINT) and Bright Green (NASDAQ:BGXX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
Windtree Therapeutics is trading at a lower price-to-earnings ratio than Bright Green, indicating that it is currently the more affordable of the two stocks.
Windtree Therapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Bright Green has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.
In the previous week, Windtree Therapeutics had 3 more articles in the media than Bright Green. MarketBeat recorded 4 mentions for Windtree Therapeutics and 1 mentions for Bright Green. Bright Green's average media sentiment score of 0.95 beat Windtree Therapeutics' score of 0.75 indicating that Bright Green is being referred to more favorably in the news media.
29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of Bright Green shares are owned by institutional investors. 0.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 62.5% of Bright Green shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Windtree Therapeutics currently has a consensus price target of $350.00, indicating a potential upside of 47,006.33%. Given Windtree Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Windtree Therapeutics is more favorable than Bright Green.
Bright Green's return on equity of -88.37% beat Windtree Therapeutics' return on equity.
Windtree Therapeutics received 3 more outperform votes than Bright Green when rated by MarketBeat users.
Summary
Windtree Therapeutics beats Bright Green on 7 of the 13 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy WINT Stock Free WINT Stock Alerts